HESTERBIOPharmaceuticals
Hester Biosciences Ltd — Profit & Loss Statement
₹1259.10
-4.49%
Hester Biosciences Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | -0.13 Cr | 0.23 Cr | -0.10 Cr | -0.48 Cr |
| Tax Rate For Calcs | 0.27 | 0.34 | 0.30 | 0.26 |
| Normalized EBITDA | 65.20 Cr | 57.55 Cr | 66.33 Cr | 74.52 Cr |
| Total Unusual Items | -0.49 Cr | 0.69 Cr | -0.33 Cr | -1.86 Cr |
| Total Unusual Items Excluding Goodwill | -0.49 Cr | 0.69 Cr | -0.33 Cr | -1.86 Cr |
| Net Income From Continuing Operation Net Minority Interest | 27.49 Cr | 18.89 Cr | 26.63 Cr | 39.32 Cr |
| Reconciled Depreciation | 16.80 Cr | 17.17 Cr | 20.70 Cr | 16.58 Cr |
| Reconciled Cost Of Revenue | 102.63 Cr | 110.18 Cr | 85.82 Cr | 72.54 Cr |
| EBITDA | 64.71 Cr | 58.25 Cr | 66.00 Cr | 72.66 Cr |
| EBIT | 47.91 Cr | 41.07 Cr | 45.30 Cr | 56.08 Cr |
| Net Interest Income | -6.79 Cr | -7.52 Cr | -3.31 Cr | -1.63 Cr |
| Interest Expense | 8.34 Cr | 9.12 Cr | 5.15 Cr | 2.58 Cr |
| Interest Income | 2.04 Cr | 1.91 Cr | 2.17 Cr | 1.90 Cr |
| Normalized Income | 27.84 Cr | 18.43 Cr | 26.86 Cr | 40.70 Cr |
| Net Income From Continuing And Discontinued Operation | 27.49 Cr | 18.89 Cr | 26.63 Cr | 39.32 Cr |
| Total Expenses | 265.86 Cr | 262.27 Cr | 224.53 Cr | 178.53 Cr |
| Rent Expense Supplemental | 2.65 Cr | 2.33 Cr | 1.54 Cr | 1.31 Cr |
| Diluted Average Shares | 0.85 Cr | 0.85 Cr | 0.85 Cr | 0.85 Cr |
| Basic Average Shares | 0.85 Cr | 0.85 Cr | 0.85 Cr | 0.85 Cr |
| Diluted EPS | 32.31 | 22.20 | 31.30 | 46.22 |
| Basic EPS | 32.31 | 22.20 | 31.30 | 46.22 |
| Diluted NI Availto Com Stockholders | 27.49 Cr | 18.89 Cr | 26.63 Cr | 39.32 Cr |
| Net Income Common Stockholders | 27.49 Cr | 18.89 Cr | 26.63 Cr | 39.32 Cr |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 27.49 Cr | 18.89 Cr | 26.63 Cr | 39.32 Cr |
| Minority Interests | -1.34 Cr | -2.28 Cr | -1.41 Cr | -0.16 Cr |
| Net Income Including Noncontrolling Interests | 28.83 Cr | 21.17 Cr | 28.04 Cr | 39.48 Cr |
| Net Income Continuous Operations | 28.83 Cr | 21.17 Cr | 28.04 Cr | 39.48 Cr |
| Tax Provision | 10.74 Cr | 10.79 Cr | 12.12 Cr | 14.02 Cr |
| Pretax Income | 39.57 Cr | 31.95 Cr | 40.15 Cr | 53.50 Cr |
| Other Non Operating Income Expenses | 0.77 Cr | 1.36 Cr | 0.81 Cr | 0.56 Cr |
| Special Income Charges | -0.49 Cr | 0.69 Cr | -0.33 Cr | -1.86 Cr |
| Other Special Charges | 0.49 Cr | -1.21 Cr | -0.02 Cr | -0.13 Cr |
| Write Off | 0.00 | 0.51 Cr | 0.34 Cr | 1.99 Cr |
| Net Non Operating Interest Income Expense | -6.79 Cr | -7.52 Cr | -3.31 Cr | -1.63 Cr |
| Total Other Finance Cost | 0.49 Cr | 0.31 Cr | 0.33 Cr | 0.96 Cr |
| Interest Expense Non Operating | 8.34 Cr | 9.12 Cr | 5.15 Cr | 2.58 Cr |
| Interest Income Non Operating | 2.04 Cr | 1.91 Cr | 2.17 Cr | 1.90 Cr |
| Operating Income | 45.24 Cr | 42.28 Cr | 41.56 Cr | 56.47 Cr |
| Operating Expense | 163.23 Cr | 152.08 Cr | 138.71 Cr | 106.00 Cr |
| Other Operating Expenses | 46.60 Cr | 43.02 Cr | 39.83 Cr | 29.08 Cr |
| Depreciation And Amortization In Income Statement | 16.80 Cr | 17.17 Cr | 20.70 Cr | 16.58 Cr |
| Depreciation Income Statement | 16.80 Cr | 17.17 Cr | 20.70 Cr | 16.58 Cr |
| Selling General And Administration | 35.07 Cr | 30.51 Cr | 31.66 Cr | 24.44 Cr |
| Selling And Marketing Expense | 28.28 Cr | 25.60 Cr | 26.34 Cr | 17.31 Cr |
| General And Administrative Expense | 6.79 Cr | 4.90 Cr | 5.32 Cr | 7.13 Cr |
| Rent And Landing Fees | 2.65 Cr | 2.33 Cr | 1.54 Cr | 1.31 Cr |
| Gross Profit | 208.47 Cr | 194.36 Cr | 180.27 Cr | 162.47 Cr |
| Cost Of Revenue | 102.63 Cr | 110.18 Cr | 85.82 Cr | 72.54 Cr |
| Total Revenue | 311.10 Cr | 304.55 Cr | 266.09 Cr | 235.01 Cr |
| Operating Revenue | 311.10 Cr | 304.55 Cr | 266.09 Cr | 235.01 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Hester Biosciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.